Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.89 |
| ▸ | EDNRB | P24530 | 12/20 | 0.89 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.89 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.89 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.89 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.89 |
| ▸ | DHPS | P49366 | 1/20 | 0.89 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.89 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29771286 | 1.00 | EDNRA (0.89) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL24612530 | 0.95 | EDNRA (0.86) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL14026692 | 0.94 | EDNRA (0.79) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL29485039 | 0.94 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL3981779 | 0.94 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL902870 | 0.94 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL4218 | 0.94 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL14026696 | 0.94 | EDNRA (0.78) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL618415 | 0.93 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL615991 | 0.93 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220025416-A1 | BIOCATALYTIC TECHNIQUES | HYPHA DISCOVERY LIMITED (GB) | 2022-01-27 | — | — | US | disclosed |
| US-20100256371-A1 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF | GLENMARK (IN) | 2010-10-07 | — | — | US | disclosed |
| US-20100256371-A1 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF | GLENMARK (IN) | 2010-10-07 | — | — | US | disclosed |
| US-6610518-B2 | Using Cytochrome p450 | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020012977-A1 | Enzymatic oxidations | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1160331-A1 | Enzymatic oxidations | Pfizer Limited (GB) | 2001-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256371-A1 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF | PTGIS, EDNRB, CYP11B2 | EDNRA 6/4885EDNRB 2/4885ABCC3 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.